FDA Adds Transparency On Paragraph IVs In Bid To Spur Competition
By disclosing when the first paragraph IV patent challenges were filed, how many players are in the race, and whether it has decided on eligibility for 180-day exclusivity, the FDA is aiming to spur greater competition in the US generics arena.
You may also be interested in...
Opioid overdose treatments containing naloxone or nalmefene are now eligible for expedited ANDA review in a bid by the FDA to improve patient access.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.